Stockscreener 앱 받기
1.86
2.62%
-0.05
시간 외 거래:
1.86
Cellectis Adr 주식(CLLS)의 최신 뉴스
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading - MSN
Cellectis's SWOT analysis: gene-editing firm's stock faces pivotal year ahead - Investing.com
Cellectis stock touches 52-week low at $1.75 amid market challenges - Investing.com
Earnings call: Cellectis reports robust cash reserves, new R&D initiatives - Investing.com
Baird maintains $10 target on Cellectis amid strong AZN partnership - Investing.com
Cellectis earnings missed by $0.03, revenue topped estimates By Investing.com - Investing.com South Africa
Cellectis earnings missed by $0.03, revenue topped estimates - Investing.com
Cellectis stock touches 52-week low at $1.77 amid market shifts By Investing.com - Investing.com South Africa
500: Something went wrong - Investing.com
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remains Down for Week - MSN
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
Monthly information on share capital and company voting rights - GlobeNewswire Inc.
Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges - Investing.com
Wall Street SWOT: Cellectis stock rides wave of innovation amid biotech challenges By Investing.com - Investing.com South Africa
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN
A year in review: Cellectis ADR (CLLS)’s performance in the last year - US Post News
Monthly information on share capital and company voting rights - GlobeNewswire Inc.
Market Insights: Cellectis ADR (CLLS)'s Notable Drop of -5.84, Closing at 2.02 – DWinneX - The Dwinnex
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors - The Globe and Mail
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results - The Globe and Mail
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading - MSN
Cellectis shares target cut by Oppenheimer on revised model post-Q1 results - Investing.com India
Cellectis shares target cut by Oppenheimer on revised model post-Q1 results By Investing.com - Investing.com UK
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower - MSN
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By Investing.com - Investing.com India
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca - Investing.com India
European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Fall Again in Tuesday Trading - MSN
CellectisADR (CLLS) Price Target Increased by 20.85% to 11.75 - MSN
AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions - AstraZeneca
There's a Lot of Upside For Emerging Gene-Editing Companies - The Globe and Mail
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing - Nature.com
Cytovia Therapeutics To Go Public Via $600 Million SPAC Merger - Equities News
Cellectis Completes Sale of $47 million through its ATM program - The Globe and Mail
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq - The Globe and Mail
Current Cathie Wood Portfolio 2021: Ark Invest Holdings - New Trader U
The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon - Yahoo Finance
30 Stocks Moving In Wednesday's Pre-Market SessionAdtran Holdings (NASDAQ:ADTN), Adient (NYSE:ADNT) - Benzinga
7 Gene Editing Companies Investors Should Watch - Nanalyze
25 Stocks Moving In Tuesday's Pre-Market SessionBioCryst Pharma (NASDAQ:BCRX) - Benzinga
25 Stocks Moving In Monday's Pre-Market SessionAltisource Portfolio (NASDAQ:ASPS) - Benzinga
Top 10 Luxury Car Brands In The World - Insider Monkey
Cellectis (CLLS) Stock Price, News & AnalysisNASDAQ - MarketBeat
Morning Market GainersCellectis (NASDAQ:CLLS) - Benzinga
New Strong Buy Stocks for October 27th - Nasdaq
BofA Starts Cellectis At Buy, Sees Plant Sciences As 'Hidden Gem'Cellectis (NASDAQ:CLLS) - Benzinga
0.93%
3.55%
자본화:
|
볼륨(24시간):